News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
734,268 Results
Type
Article (45954)
Company Profile (311)
Press Release (688003)
Multimedia
Podcasts (100)
Webinars (12)
Section
Business (214558)
Career Advice (2288)
Deals (37421)
Drug Delivery (118)
Drug Development (84731)
Employer Resources (179)
FDA (16865)
Job Trends (15675)
News (363511)
Policy (34990)
Tag
Academia (2677)
Accelerated approval (5)
Adcomms (26)
Allergies (92)
Alliances (52551)
ALS (95)
Alzheimer's disease (1425)
Antibody-drug conjugate (ADC) (147)
Approvals (16849)
Artificial intelligence (280)
Autoimmune disease (26)
Automation (16)
Bankruptcy (380)
Best Places to Work (11889)
BIOSECURE Act (22)
Biosimilars (118)
Biotechnology (196)
Bladder cancer (79)
Brain cancer (29)
Breast cancer (285)
Cancer (2340)
Cardiovascular disease (191)
Career advice (1911)
Career pathing (33)
CAR-T (160)
Cell therapy (446)
Cervical cancer (19)
Clinical research (68809)
Collaboration (884)
Compensation (539)
Complete response letters (29)
COVID-19 (2739)
CRISPR (46)
C-suite (254)
Cystic fibrosis (103)
Data (2226)
Decentralized trials (2)
Denatured (30)
Depression (48)
Diabetes (286)
Diagnostics (6535)
Digital health (18)
Diversity (9)
Diversity, equity & inclusion (46)
Drug discovery (126)
Drug pricing (121)
Drug shortages (31)
Duchenne muscular dystrophy (99)
Earnings (89735)
Editorial (43)
Employer branding (21)
Employer resources (154)
Events (117546)
Executive appointments (754)
FDA (18140)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (777)
Gene editing (114)
Generative AI (24)
Gene therapy (329)
GLP-1 (804)
Government (4718)
Grass and pollen (5)
Guidances (59)
Healthcare (19342)
Huntington's disease (24)
IgA nephropathy (30)
Immunology and inflammation (135)
Indications (30)
Infectious disease (2893)
Inflammatory bowel disease (143)
Inflation Reduction Act (8)
Influenza (53)
Intellectual property (99)
Interviews (360)
IPO (17057)
IRA (48)
Job creations (4208)
Job search strategy (1631)
Kidney cancer (11)
Labor market (38)
Layoffs (513)
Leadership (23)
Legal (8690)
Liver cancer (77)
Lung cancer (331)
Lymphoma (156)
Machine learning (7)
Management (61)
Manufacturing (336)
MASH (72)
Medical device (13632)
Medtech (13637)
Mergers & acquisitions (20910)
Metabolic disorders (758)
Multiple sclerosis (85)
NASH (21)
Neurodegenerative disease (101)
Neuropsychiatric disorders (33)
Neuroscience (2000)
NextGen: Class of 2025 (6776)
Non-profit (4597)
Now hiring (39)
Obesity (411)
Opinion (252)
Ovarian cancer (78)
Pain (96)
Pancreatic cancer (84)
Parkinson's disease (158)
Partnered (21)
Patents (245)
Patient recruitment (111)
Peanut (50)
People (60391)
Pharmaceutical (98)
Pharmacy benefit managers (21)
Phase I (21444)
Phase II (30191)
Phase III (22661)
Pipeline (1217)
Policy (163)
Postmarket research (2728)
Preclinical (9084)
Press Release (68)
Prostate cancer (110)
Psychedelics (34)
Radiopharmaceuticals (259)
Rare diseases (409)
Real estate (6476)
Recruiting (68)
Regulatory (23783)
Reports (46)
Research institute (2425)
Resumes & cover letters (380)
Rett syndrome (5)
RNA editing (5)
RSV (48)
Schizophrenia (78)
Series A (135)
Series B (88)
Service/supplier (14)
Sickle cell disease (55)
Special edition (17)
Spinal muscular atrophy (153)
Sponsored (31)
Startups (3829)
State (2)
Stomach cancer (15)
Supply chain (74)
Tariffs (45)
The Weekly (68)
Vaccines (737)
Venture capitalists (41)
Weight loss (291)
Women's health (37)
Worklife (17)
Date
Today (178)
Last 7 days (890)
Last 30 days (2720)
Last 365 days (33906)
2025 (10999)
2024 (36351)
2023 (41160)
2022 (52386)
2021 (56922)
2020 (55451)
2019 (48182)
2018 (36451)
2017 (33933)
2016 (33632)
2015 (39468)
2014 (33429)
2013 (28591)
2012 (30666)
2011 (31335)
2010 (29332)
Location
Africa (830)
Alabama (53)
Alaska (7)
Arizona (243)
Arkansas (14)
Asia (43746)
Australia (6783)
California (6181)
Canada (2031)
China (559)
Colorado (273)
Connecticut (279)
Delaware (152)
Europe (91065)
Florida (926)
Georgia (207)
Idaho (57)
Illinois (556)
India (27)
Indiana (322)
Iowa (11)
Japan (167)
Kansas (104)
Kentucky (23)
Louisiana (10)
Maine (62)
Maryland (911)
Massachusetts (4671)
Michigan (221)
Minnesota (394)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (64)
New Hampshire (63)
New Jersey (1761)
New Mexico (31)
New York (1760)
North Carolina (1032)
North Dakota (8)
Northern California (2688)
Ohio (210)
Oklahoma (14)
Oregon (40)
Pennsylvania (1386)
Puerto Rico (13)
Rhode Island (33)
South America (1212)
South Carolina (22)
South Dakota (1)
Southern California (2317)
Tennessee (102)
Texas (921)
United States (23538)
Utah (185)
Virginia (154)
Washington D.C. (64)
Washington State (561)
West Virginia (3)
Wisconsin (57)
734,268 Results for "china pharma holdings inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
China
Big Pharma Rushes to China for Deal Prospecting Despite Regulatory Uncertainty
China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.
January 7, 2025
·
6 min read
·
Annalee Armstrong
China
AstraZeneca Makes Potential $10B+ China Commitment Despite Political Pressure
The investments come amid an ongoing insurance fraud probe into AstraZeneca’s former China head Leon Wang—and despite mounting pressure from President Trump for pharma companies to re-shore their manufacturing operations.
March 24, 2025
·
2 min read
·
Tristan Manalac
Tariffs
China Still Go-To Source for New Drugs Despite Tariff Minefield
Policy uncertainties are impacting biopharma dealmaking from continent to continent, with companies being asked to walk a tightrope on their relations with China.
April 30, 2025
·
10 min read
·
Annalee Armstrong
China Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split
China Pharma Holdings Inc. reported that it expects to implement a 1-for-5 reverse stock split on its common stock effective Wednesday, March 6, 2024, with trading to begin on a split-adjusted basis at the market open on that day.
February 23, 2024
·
3 min read
Mergers & acquisitions
AstraZeneca Buys FibroGen’s China Unit for $160M as Probes Continue
A year ago, AstraZeneca walked away from the bulk of its roxadustat partnership with FibroGen—though the pharma at the time decided to retain its relationship with the biotech’s China operations.
February 20, 2025
·
2 min read
·
Tristan Manalac
China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device
China Pharma Holdings, Inc. announced that its Dry Eye Disease therapeutic device has passed third-party testing and is preparing to apply for market launch to the National Medical Products Administration of China.
November 29, 2023
·
3 min read
China
The Rise of China Innovation in the Time of Trump
With incoming president Donald Trump threatening a trade war with China, experts told
BioSpace
that the new administration will likely understand why medicines should be treated differently.
January 16, 2025
·
4 min read
·
Annalee Armstrong
Press Releases
Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris
February 27, 2025
·
5 min read
Government
Trump Tariffs Miss Pharma For Now, But Uncertainties Loom
Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector-specific duties “in the next month or so.”
April 3, 2025
·
2 min read
·
Tristan Manalac
Compensation
Top 6 Highest-Paid Pharma CEOs in 2024
Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.
April 16, 2025
·
7 min read
·
Annalee Armstrong
1 of 73,427
Next
